Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2013
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsXiaohua Huang, Cliff C Cheng, Thierry O Fischmann, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Genes|October 27, 2022
Robust Genetic Analysis of the X-Linked Anophthalmic (Ie) MouseBrianda A Hernandez-Moran, Andrew S Papanastasiou, David Parry, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Nature Communications|April 26, 2017
Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesisAmy T Y Yeung, Christine Hale, Amy H Lee, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Pageof 12